Abigail Brooks, MA

Ritter reviews findings from 2 real-world studies supporting the safety and efficacy of live-jslm (Rebyota) for recurrent C Diff infection.

Lacy explains limitations to current motility measurements and reviews findings from his study exploring the potential of a wireless motility patch system.

Liver-related mortality in the US increased by nearly 20% from 2018, with lower transplant rates observed in states with the greatest mortality.

HCV infection was associated with elevated brachial-ankle pulse wave velocity levels in patients with ESRD receiving hemodialysis.

Patients with greater HADS-D scores were less likely to achieve symptomatic response or remission with a 2-step dietary intervention for IBS.

The FDA has extended its review of the sNDA, delaying the previous October 15, 2024, PDUFA date, without providing a new anticipated action date.

Adherence to an adapted low FODMAP diet and its impact on IBS symptoms were not affected based on the presence of fibromyalgia.

Patients who underwent FESS required less medication and had fewer allergy and pulmonology visits than patients who did not have surgery.

Proof-of-mechanism data from the phase 1b/2a study of WVE-006 represent the first-ever clinical demonstration of RNA editing in humans.

The literature review suggests allergen immunotherapy can effectively treat allergic asthma and prevent its development in patients with allergic rhinitis.

Findings highlight the potential utility of the FAST score for ruling out fibrotic MASH, pointing to the need for a sequential testing approach to rule it in.

Study findings showed children with both obesity and MASLD have a greater risk of youth-onset type 2 diabetes than those with obesity alone.

Linaclotide was safe and effective for patients with chronic constipation and IBS with constipation who switched after non-response to magnesium oxide.

In focus groups, patients indicated symptom bothersomeness and life interference should be included in clinical evaluation for disorders of gut-brain interaction.

New phase 2b data highlight denifanstat’s impact on histological features of MASH, meeting both fibrosis improvement and MASH resolution primary endpoints.

Findings support the feasibility and clinical performance of Xpert HCV, the first FDA-approved point-of-care test for diagnosing HCV, in a nonclinical justice setting.

Findings suggest obstetric complications are associated with more severe psychopathological phenotypes in schizophrenia and related disorders.

The designation was granted to Mirum Pharmaceuticals based on a positive interim analysis of the phase 2b VANTAGE study of volixibat.

Findings highlight high healthcare resource utilization and costs but low psychotherapy utilization, frequent relapse, and pharmacologic therapy discontinuation.

Saggese explains the importance of second-line therapies in PBC, newly approved treatment options, and their impact on treatment goals and timelines.

Younossi explains how MASH negatively impacts patients’ quality of life and describes resmetirom’s benefit across multiple HRQoL domains.

In addition to the Breakthrough Therapy Designation, Boehringer Ingelheim announced the initiation of 2 phase 3 trials in adults with MASH and fibrosis and compensated MASH cirrhosis.

Findings highlight HCV infection burden among people without injection drug use, a known risk factor for HCV, and call for universal testing to better capture these individuals.

This September 2024 month in review spotlights our top coverage of recent nephrology pipeline updates, guidelines, and research.

Patients taking GLP-1 RAs were more likely to show food retention and inadequate bowel preparation, even when the medications were held before the procedure.

Study findings highlight the individual and combined impact of smoking tobacco and drinking alcohol on achieving PASI75 after 8 weeks of treatment.

The approval is based on findings from BLUE-C, where Cologuard Plus demonstrated sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity.

Contrary to previous research, findings suggest no significant difference in infertility between patients with HS, other dermatological diseases, and healthy controls.

Gross hematuria after COVID-19 mRNA vaccination was more likely in females, patients with IgAN/IgAV, and after the second and third vaccine doses.

This month in review spotlights recent GI pipeline news, new research about IBS and other gastroenterological conditions, and coverage from the 2024 GHAPP conference.